期刊
NANOMEDICINE
卷 16, 期 18, 页码 1595-1611出版社
FUTURE MEDICINE LTD
DOI: 10.2217/nnm-2021-0104
关键词
Alzheimer's disease; blood-brain barrier; quantum dots; theranostics; toxicity
资金
- Yulgibar/Dementia Australia
- National Health and Medical Research Council (NHMRC), Australia [GNT1139060]
Quantum dots, as nanoparticles, hold promising applications in neurodegenerative diseases due to their unique optical properties and versatility. Their ability to conjugate to various biomolecules while maintaining a nanoscale size makes them a potential tool in Alzheimer's disease diagnosis and therapy.
Aim: Quantum dots (QDs) are nanoparticles that have an emerging application as theranostic agents in several neurodegenerative diseases. The advantage of QDs as nanomedicine is due to their unique optical properties that provide high sensitivity, stability and selectivity at a nanoscale range. Objective: To offer renewed insight into current QD research and elucidate its promising application in Alzheimer's disease (AD) diagnosis and therapy. Methods: A comprehensive literature search was conducted in PubMed and Google Scholar databases that included the following search terms: 'quantum dots', 'blood-brain barrier', 'cytotoxicity', 'toxicity' and 'Alzheimer's disease'; PRISMA guidelines were adhered to. Results: Thirty-four publications were selected to evaluate the ability of QDs to cross the blood-brain barrier, potential toxicity and current AD diagnostic and therapeutic applications. Conclusion: QD's unique optical properties and versatility to conjugate to various biomolecules, while maintaining a nanoscale size, render them a promising theranostic tool in AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据